Across TCGA pan-cancer cohorts, SMIM10L2B-AS1 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of SMIM10L2B-AS1’s most consistent transcriptional readouts.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SMIM10L2B-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SMIM10L2B-AS1 is over-expressed in tumor.
KIRC, KIRP, and UCEC are the cancer types where SMIM10L2B-AS1 tumor–normal differential expression is most reproducible.